Tissue Regenix Group plc
TRX.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | -2.9% | 20.5% | 24% | – |
| Cost of Goods Sold | £0 | £0 | £0 | £0 |
| Gross Profit | £0 | £0 | £0 | £0 |
| % Margin | 47.5% | 47.6% | 37.3% | 28.5% |
| R&D Expenses | £0 | £0 | £0 | £0 |
| G&A Expenses | £0 | £0 | £0 | £0 |
| SG&A Expenses | £0 | £0 | £0 | £0 |
| Sales & Mktg Exp. | £0 | £0 | -£0 | -£0 |
| Other Operating Expenses | £0 | £0 | £0 | £0 |
| Operating Expenses | £0 | £0 | £0 | £0 |
| Operating Income | £0 | -£0 | -£0 | -£0 |
| % Margin | 1.2% | -1.3% | -8.2% | -22.2% |
| Other Income/Exp. Net | -£0 | -£0 | -£0 | -£0 |
| Pre-Tax Income | -£0 | -£0 | -£0 | -£0 |
| Tax Expense | £0 | -£0 | -£0 | -£0 |
| Net Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -2.5% | -5.8% | -11% | -24.3% |
| EPS | -0.01 | -0.024 | -0.031 | -0.068 |
| % Growth | 58.4% | 21.9% | 54.3% | – |
| EPS Diluted | -0.01 | -0.024 | -0.031 | -0.068 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | -£0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £0 | £0 | £0 | £0 |
| EBITDA | £0 | £0 | -£0 | -£0 |
| % Margin | 4.8% | 1.5% | -4.2% | -15.4% |